The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


The Journal of Immunology, 2007, 179, 6043 -6051
Copyright © 2007 by The American Association of Immunologists, Inc.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Decologne, N.
Right arrow Articles by Bonniaud, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Decologne, N.
Right arrow Articles by Bonniaud, P.

TGF-beta1 Induces Progressive Pleural Scarring and Subpleural Fibrosis1

Nathalie Decologne*, Martin Kolb{ddagger}, Peter J. Margetts{ddagger}, Franck Menetrier*, Yves Artur{dagger}, Carmen Garrido*, Jack Gauldie{ddagger}, Philippe Camus*,§ and Philippe Bonniaud2,*,§

* Faculty of Medicine and Pharmacy, Institut National de la Santé et de la Recherche Médicale (INSERM), Unité Mixte de Recherche (UMR) 866, Dijon, France; {dagger} UMR 1129, Flaveur, Vision et Comportement du Consommateur, Institut National de la Recherche Agronomique, Etablissement National d’Enseignement Supérieur Agronomique de Dijon, University of Burgundy, Dijon, France; {ddagger} Department of Pathology and Molecular Medicine, Centre for Gene Therapeutics, McMaster University, Hamilton, Ontario, Canada; and § Service de Pneumologie et Réanimation Respiratoire, Centre Hospitalier Universitaire du Bocage, Dijon, France

Pleural fibrosis is a misunderstood disorder which can cause severe restrictive lung disease with high morbidity and even mortality. The condition can develop in response to a large variety of diseases and tissue injury, among them infectious disease, asbestos, drugs, and radiation therapy. There is no efficient treatment to reverse established pleural fibrosis. TGF-beta1 is suspected, even if not proven, as a key cytokine in this process. In this study, we used adenoviral gene transfer of TGF-beta1 to the pleural mesothelium in rats. We show that local and transient TGF-beta1 overexpression induces homogenous, prolonged, and progressive pleural fibrosis without pleurodesis, associated with severe impairment of pulmonary function. We further demonstrate that pleural fibrosis can expand into the lung parenchyma from the visceral layer, but not into the muscle from the parietal layer. We provide evidence that matrix accumulation and fibrosis within the parenchyma evolved through a process involving "mesothelial-fibroblastoid transformation" and suggest that the pleural mesothelial cell may be an important player involved in the development of the subpleural distribution pattern known to be a hallmark of pulmonary fibrosis. This new model of pleural fibrosis will allow us to better understand the mechanisms of progressive fibrogenesis, and to explore novel antifibrotic therapies in the pleural cavity.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 N.D. was supported by the Comité de Côte d’Or de la Ligue Contre le Cancer and by the Société de Pneumologie de Langue Française. P.B. was supported by Pneumologie Développement. M.K. is a Parker B. Francis Fellow and was supported by a Career Development Award of Department of Medicine, McMaster University. P.J.M. is a Canadian Institutes for Health Research Clinician Scientist.

2 Address correspondence and reprint requests to Dr. Philippe Bonniaud, Service de Pneumologie et Réanimation Respiratoire, Centre Hospitalier Universitaire du Bocage, 21079 Dijon, France. E-mail address: philippe.bonniaud{at}chu-dijon.fr

3 Abbreviations used in this paper: EMT, epithelial-to-mesenchymal transition; MFT, mesothelial-fibroblastoid transformation; PLF, pleural lavage fluid; BAL, bronchoalveolar lavage; BALF, BAL fluid; HSP, heat shock protein; SMA, smooth muscle actin; MMP, matrix metalloproteinase.




This article has been cited by other articles:


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
N. Nasreen, K. A. Mohammed, K. K. Mubarak, M. A. Baz, O. A. Akindipe, S. Fernandez-Bussy, and V. B. Antony
Pleural mesothelial cell transformation into myofibroblasts and haptotactic migration in response to TGF-{beta}1 in vitro
Am J Physiol Lung Cell Mol Physiol, July 1, 2009; 297(1): L115 - L124.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
N. W. Clavin, T. Avraham, J. Fernandez, S. V. Daluvoy, M. A. Soares, A. Chaudhry, and B. J. Mehrara
TGF-{beta}1 is a negative regulator of lymphatic regeneration during wound repair
Am J Physiol Heart Circ Physiol, November 1, 2008; 295(5): H2113 - H2127.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
J. Que, B. Wilm, H. Hasegawa, F. Wang, D. Bader, and B. L. M. Hogan
Mesothelium contributes to vascular smooth muscle and mesenchyme during lung development
PNAS, October 28, 2008; 105(43): 16626 - 16630.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2007 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2007 by The American Association of Immunologists, Inc. All rights reserved.